Summit Therapeutics vs Solventum

Summit Therapeutics (SMMT), health care, and Solventum (SOLV), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Solventum is worth $14.6B on the stock market and Summit Therapeutics $8.5B: Solventum is valued at 71% more. Over the past year Summit Therapeutics's share price has moved -29.7% and Solventum's +15.3%.

Key facts

Summit Therapeutics market value
$8.5B
Solventum market value
$14.6B
Solventum P/E
100
Solventum revenue
$8.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Summit Therapeutics vs Solventum: every measure side by side
Measure Summit Therapeutics Solventum
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$8.5Blower$14.6Bhigher
Revenue—$8.3B
Earnings-$1.1Blower$1.6Bhigher
Employees265lower20,584higher
Total assets$751.2Mlower$14.3Bhigher
Valuation
P/E—100
P/S—1.8
P/B15.1higher3.0lower
Dividend yield0.00%0.00%
Profitability
Operating margin—26.2%
Balance sheet
Net assets$658.9Mlower$5Bhigher
Total liabilities$92.3Mlower$9.2Bhigher
Total debt—$5B
Cash on hand$225.3Mlower$878Mhigher
Price change
Today-9.73%lower-2.92%higher
1 year-29.7%lower+15.3%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Summit Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns SMMT · Who owns SOLV

Further comparisons

Learn

Questions and answers

Which is bigger, Summit Therapeutics or Solventum?

By market value, Solventum is the larger: $14.6B against $8.5B for Summit Therapeutics.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Summit Therapeutics and Solventum?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Summit Therapeutics and 6 hold Solventum.

Cite this page

Funkfolio, “Summit Therapeutics vs Solventum”, data as of 18 November 2026. https://funkfolio.com/compare/smmt-vs-solv

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.